Evidence map›Paper›PMID 28444928›Full record

ArticlePhytotherapy research : PTR2017

Antiinflammatory Activity of Cinnamon (Cinnamomum zeylanicum) Bark Essential Oil in a Human Skin Disease Model.

Xuesheng Han, Tory L Parker

Open access · hybridAbstract read
In one paragraph

Article in Phytotherapy research : PTR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
10.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 100 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Molecules (Basel, Switzerland) · 2022
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xuesheng HandōTERRA International, LLC, 389 S. 1300 W, Pleasant Grove, UT, 84062, USA.ORCID http://orcid.org/0000-0003-2720-3011
Tory L ParkerdōTERRA International, LLC, 389 S. 1300 W, Pleasant Grove, UT, 84062, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effect of cinnamon (Cinnamomum zeylanicum) bark essential oil (CBEO) on human skin cells has not been elucidated. Therefore, we investigated the activity of a commercially available CBEO in a validated human dermal fibroblast system, a model of chronic inflammation and fibrosis. We first evaluated the impact of CBEO on 17 protein biomarkers that play critical roles in inflammation and tissue remodeling. The impact of CBEO on genome-wide gene expression was also evaluated. CBEO showed strong anti-proliferative effects on skin cells and significantly inhibited the production of several inflammatory biomarkers, including vascular cell adhesion molecule-1, intercellular cell adhesion molecule-1, monocyte chemoattractant protein-1, interferon gamma-induced protein 10, interferon-inducible T-cell alpha chemoattractant, and monokine induced by gamma interferon. In addition, CBEO significantly inhibited the production of several tissue remodeling molecules, including epidermal growth factor receptor, matrix metalloproteinase-1, and plasminogen activator inhibitor-1. Macrophage colony-stimulating factor, which is an immunomodulatory protein molecule, was also significantly inhibited by CBEO. Furthermore, CBEO significantly modulated global gene expression and altered signaling pathways, many of which are important in inflammation, tissue remodeling, and cancer biology. The study shows that CBEO is a promising antiinflammatory agent; however, further research is required to clarify its clinical efficacy. © 2017 The Authors. Phytotherapy Research published by John Wiley & Sons Ltd.

Indexed as

Anti-Inflammatory AgentsCells, CulturedChemokine CCL2Chemokine CXCL10Cinnamomum zeylanicumFibroblastsHumansIntercellular Adhesion Molecule-1Macrophage Colony-Stimulating FactorMatrix Metalloproteinase 1Oils, VolatilePhytotherapyPlant BarkPlant ExtractsPlasminogen Activator Inhibitor 1Skin DiseasesAnti-Inflammatory AgentsCCL2 protein, humanChemokine CCL2Chemokine CXCL10CXCL10 protein, humanIntercellular Adhesion Molecule-1Macrophage Colony-Stimulating FactorMatrix Metalloproteinase 1MMP1 protein, humanOils, VolatilePlant ExtractsPlasminogen Activator Inhibitor 1SERPINE1 protein, humanVascular Cell Adhesion Molecule-1cell proliferationcinnamon bark essential oilgenome-wide gene expressioninflammationMIGVCAM-1

Identifiers

PMID28444928
PMCPMC5518441
OpenAlexW2609063923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.